PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

• Status: Completed
• Trial end date: 2012-07-03
• Target enrollment: 0
• Participant gender: All

Summary

To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Patients age 20 or older, regardless of gender.

• Receiving stable maintenance hemodialysis 3 times a week.

• Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.

Exclusion Criteria:

• Patients having history of a pronounced brain / cardiovascular disorder.

• Patients having severe gastrointestinal disorders.

• Patients having severe hepatic disorders.